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ARTICLE
Cellular and Molecular Biology
Immune status is prognostic for poor survival in colorectal
cancer patients and is associated with tumour hypoxia
Stephanie G. Craig1, Matthew P. Humphries1, Matthew Alderdice1, Victoria Bingham1, Susan D. Richman2, Maurice B. Loughrey3,4,
Helen G. Coleman4, Amelie Viratham-Pulsawatdi1, Kris McCombe1, Graeme I. Murray5, Andrew Blake6, Enric Domingo6,
James Robineau6, Louise Brown7, David Fisher7, Matthew T. Seymour2, Phil Quirke2, Peter Bankhead8, Stephen McQuaid1,3,
Mark Lawler1, Darragh G. McArt1, Tim S. Maughan6, Jacqueline A. James1,3 and Manuel Salto-Tellez 1,3
BACKGROUND: Immunohistochemical quantification of the immune response is prognostic for colorectal cancer (CRC). Here, we
evaluate the suitability of alternative immune classifiers on prognosis and assess whether they relate to biological features
amenable to targeted therapy.
METHODS: Overall survival by immune (CD3, CD4, CD8, CD20 and FOXP3) and immune-checkpoint (ICOS, IDO-1 and PD-L1)
biomarkers in independent CRC cohorts was evaluated. Matched mutational and transcriptomic data were interrogated to identify
associated biology.
RESULTS: Determination of immune-cold tumours by combined low-density cell counts of CD3, CD4 and CD8
immunohistochemistry constituted the best prognosticator across stage II–IV CRC, particularly in patients with stage IV disease (HR
1.98 [95% CI: 1.47–2.67]). These immune-cold CRCs were associated with tumour hypoxia, confirmed using CAIX
immunohistochemistry (P= 0.0009), which may mediate disease progression through common biology (KRAS mutations, CRIS-B
subtype and SPP1 mRNA overexpression).
CONCLUSIONS: Given the significantly poorer survival of immune-cold CRC patients, these data illustrate that assessment of CD4-
expressing cells complements low CD3 and CD8 immunohistochemical quantification in the tumour bulk, potentially facilitating
immunophenotyping of patient biopsies to predict prognosis. In addition, we found immune-cold CRCs to associate with a difficult-
to-treat, poor prognosis hypoxia signature, indicating that these patients may benefit from hypoxia-targeting clinical trials.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0985-5
BACKGROUND
The immune context of the tumour microenvironment is a
recognised hallmark of cancer development, recurrence and
response to therapy.1 The literature in particular denotes the
importance of adaptive immunity in cancer-related outcomes, given
that upregulation of its inflammatory mediators is consistently
associated with improved prognosis.2,3
This has been the rationale behind the development of
colorectal cancer (CRC)-specific immune-related prognostication
systems that aim to establish the likelihood of disease progres-
sion.4–6 The feasibility of at least one of these algorithms as a
diagnostic test within routine clinical practice has been validated
in a large multicentre, multi-cohort, retrospective study for stage
I–III colon cancer.5 However, in spite of its potential clinical
deployment, it remains unclear if the success of immune
prognostication in CRC, in the absence of receiving immunother-
apy, is based on the increased expression of specific immune
biomarkers alone, or the cumulative sum of the numerous
immune responses in the tumour.7
In this study, we describe the assessment of immune (CD3, CD4,
CD8, CD20 and FOXP3) and immune-checkpoint (ICOS, IDO-1 and
PD-L1) biomarkers using digital image analysis in stage II–IV CRC
patients (n= 1724). We evaluate which is the most useful
biomarker, or a combination thereof, to predict survival in CRC
at diagnosis. We identify the biology behind the prognostic
groups by analysing their mutational profile and their relationship
to the consensus molecular and CRC intrinsic subtypes (CMS and
CRIS, respectively). We complement this by conducting differential
gene expression analysis, gene set enrichment analysis (GSEA) and
orthogonal validation.8,9 Using these data, we determine which
characteristics of the tumour microenvironment mediate the
immune response and ultimately patient outcome.
www.nature.com/bjc
Received: 16 December 2019 Revised: 9 June 2020 Accepted: 23 June 2020
1Precision Medicine Centre of Excellence, Centre for Cell Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland; 2Leeds Institute of Medical Research at St
James’s, University of Leeds, Leeds, UK; 3Department of Cellular Pathology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland; 4Centre for
Public Health, Queen’s University Belfast, Belfast, Northern Ireland; 5Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland;
6CRUK/MRC Oxford Institute for Radiation Oncology, Oxford University, Oxford, England; 7MRC Clinical Trials Unit, University College London, London, UK and 8Division of
Pathology, University of Edinburgh, Edinburgh, Scotland
Correspondence: Manuel Salto-Tellez (m.salto-tellez@qub.ac.uk)
These authors contributed equally: Stephanie G. Craig, Matthew P. Humphries, Jacqueline A. James, Manuel Salto-Tellez
© The Author(s) 2020 Published by Springer Nature on behalf of Cancer Research UK
MATERIALS AND METHODS
Patients
The immune component of the tumour microenvironment was
assessed in three retrospectively identified cohorts of patients
with resections of primary CRC, ranging from stages II to IV (n=
1724). Discovery was performed in the population-representative
Epi700 CRC cohort that consists of stage II and III CRC patients
(n= 661) who underwent surgery in Northern Ireland from 2004
to 2008 (NIB13/0069, NIB13/0087, NIB13/0088 and NIB15/0168).
The results were cross-validated in the Grampian CRC cohort that
consists of stage II–III CRC patients (n= 678) diagnosed within the
Grampian National Health Service Scotland from 1994 to 2009,
accessed through the Grampian Biorepository (TR000157; OREC
17/YH/0415). Study methodology was then applied de novo (in
collaboration with the Stratification in Colorectal Cancer (S:CORT)
consortium) to the S:CORT FOCUS cohort of stage IV CRC patients
(n= 385), who were enrolled in the MRC FOCUS clinical trial (OREC
15/EE/0241).
CRC patients in the Epi700 CRC and Grampian CRC cohorts
were surgically managed with or without chemotherapy in
accordance with contemporaneous treatment guidelines at the
time of diagnosis. Details of the MRC FOCUS trial cohort have
been reported in detail elsewhere (Supplementary Fig. S1).10
Microsatellite-instability (MSI) status was assessed by PCR in the
Epi700 CRC cohort, immunohistochemistry in the Grampian CRC
cohort using antibodies (MLH1 and MSH2) and next-generation
sequencing in the S:CORT FOCUS cohort as described
previously.11,12 Overall survival (OS) was used as the primary
clinical endpoint in all three cohorts. OS was defined as the time
from either diagnosis (Epi700 CRC and Grampian CRC cohorts) or
randomisation (S:CORT FOCUS cohort) until the time of death.
Data were right-censored for patients still alive at the date of the
last known follow-up.
Procedures
Patient material for the three cohorts under assessment was
provided as 4-µm, formalin-fixed paraffin-embedded tissue sec-
tions from tissue microarrays (TMA) containing 0.6–1.0-mm tumour
cores. Immune analysis assays in tissue have been developed
primarily for use in full-face tissue sections. However, patient
material for the three cohorts under assessment was only available
in TMA format with variable TMA design, and only full-face sections
from patients within the discovery cohort were available to confirm
TMA findings. TMA construction of the Epi700 CRC and Grampian
CRC cohorts has been reported previously.11,12 In brief, TMAs for
the Epi700 CRC cohort were constructed using cores taken from
tumour epithelial-rich areas (central tumour) and the invasive
margin, whereas TMA cores representing the invasive margin were
not available for either the Grampian CRC or S:CORT FOCUS
cohorts. TMAs for the S:CORT FOCUS cohort were constructed
using 0.6-mm cores taken in triplicate from epithelial-rich tumour
regions in formalin-fixed paraffin- embedded blocks for each
patient using a Beecher manual arrayer (Beecher Instruments Inc.,
Sun Prairie, Wisconsin, USA).
All work on the TMA sections was undertaken blinded to clinical
outcomes in the Precision Medicine Centre of Excellence at
Queen’s University Belfast using standardised operating proce-
dures for immunohistochemical staining, digital slide scanning
and digital image analysis to reduce potential sources of bias in
data collection. All procedures were reviewed and agreed by
senior consultant pathologists (J.J., M.B.L. and M.S.T.).
Immunohistochemistry was performed for adaptive immune
(CD3, CD4, CD8, CD20 and FOXP3) and immune-checkpoint (ICOS,
IDO-1 and PD-L1) biomarkers on either the Ventana BenchMark XT
(Ventana Medical Systems, Oro Valley, Arizona, USA) or Leica
BOND-MAX (Leica Biosystems, Wetzlar, Germany) automated
immunostainers. Multiplex immunofluorescence for CD3, CD4
and CD8 was conducted using opal chemistry on the Leica BOND-
MAX (Leica Biosystems, Wetzlar, Germany) automated immunos-
tainer. Antibody optimisation was conferred and agreed upon
with senior consultant pathologists (J.J. and M.S.T.) prior to the
study (Supplementary Table S1). All immunostained slides were
scanned using a Leica Aperio AT2 at ×40 magnification or an
Akoya Vectra Polaris at ×20 magnification using MOTIF scanning
protocols if immunoflorescently stained. All scans were indepen-
dently reviewed for quality and consistency by trained senior
technicians (V.B. and A.V.P.) and a consultant clinical scientist
(SMcQ), before they were considered for digital image analysis.
Immunohistochemistry for the hypoxia biomarker CAIX on the S:
CORT FOCUS TMAs was carried out by the Leeds Institute of
Medical Research at St James’s using the DAKO Autostainer Link
48 (Agilent Technologies, Santa Clara, California, USA) (Supple-
mentary Table S1).
Assessment of all biomarkers was undertaken using open-
source software QuPath version 0.2.0.m6 (Fig. 1).13 Full-face
sections cut at 4 µm were annotated with the assistance of a
senior consultant pathologist (M.S.T.). Assessment of the invasive
margin on full-face CRC tissue sections was defined as a 500-µm
CD3 CD4 CD8 FOXP3 ICOS IDO-1 PD-L1Biomarker
IHC staining
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Fig. 1 Representative images of immune and immune-checkpoint biomarker staining, and their cell detection mask overlays used in
their digital image analysis. Methods of assessment are as listed. *CD3- and CD8-expressing cells as a value of positive cells per mm2 were
also assessed within the invasive margin when appropriate.
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border, taken from the outermost edge of the malignant glands.14
Quantification of CD4-expressing cells in singleplex immunohis-
tochemistry and multiplex immunofluorescence experiments by
digital image analysis was compared with “calculated” CD4 cell
counts, obtained from subtracting the number of CD8- from CD3-
expressing cells, using normal colonic epithelium. Multiplex
findings were validated on full-face resection specimens of CRC
tissue. Assessment of the immune biomarkers was taken as an
average over the number of cores available. All analysed images
were independently reviewed for quality-control purposes, with at
least 20% being reviewed by a pathologist prior to data export.
For discovery purposes, all biomarkers assessed were dichoto-
mised using Youden’s J statistic by ROC curve analysis based on
survival outcomes.
CRC data matrices for gene expression analysis in the S:CORT
FOCUS cohort were provided by the S:CORT consortium. In brief,
mutational data were generated for common driver genes APC,
BRAF, KRAS, NRAS, PIK3CA and TP53 using next-generation
sequencing (at Wellcome Trust Sanger Institute), while gene
expression data were generated using the Almac Xcel array (at
Almac Diagnostics, Craigavon).15 Gene expression data were pre-
processed and normalised using robust multi-array analysis and
probes collapsed by mean. CRIS and CMS classification was
implemented using R packages CRISclassifier and CMSclassifier,
respectively.8,9 Differential gene expression analysis, principal
component analysis (PCA) and hierarchical clustering were
performed using Partek® Genomics Suite® software version 6.6.
A list of differentially expressed probes was generated using
analysis of variance (ANOVA) with a threshold of +/−1.5-fold
change and an adjusted p value of less than 0.05. Heatmaps with
hierarchical clustering were constructed using Ward’s linkage and
Euclidean distance. Row-expression values were standardised to a
mean of zero and scaled to a standard deviation of one. GSEA
using the WINTERS_HYPOXIA metagene signature was performed
using the Broad Institute software (http://software.broadinstitute.
org/gsea/index.jsp).
Statistical analysis
All statistical analyses were conducted using R version 3.5.1. The
missing indicator method was used to handle missing clinical
data.16 Assessment for correlation, accuracy and precision of
sample classification without the invasive margin was conducted.
An overall 5-year survival analysis was visualised using the
Kaplan–Meier method with log-rank P values. Cox proportional-
hazard models were used to calculate hazard ratios (HR) and
associated 95% confidence intervals (CI) for univariate and
multivariable analysis for potential confounders as conducted
elsewhere (age, sex, stage, MSI status and treatment).5 Compe-
titive model selection on non-nested immune biomarker models
was based on log likelihood (LL) using second-order Akaike’s
Information Criterion (AICc). Models with a difference in AIC
of four or more were not considered competitive. ANOVA
and Pearson’s chi-squared were used to test for differences in
continuous and categorical variables, respectively, across the
immune subgroups. Pearson’s product–moment and Spearman
rank-order correlations were conducted to assess linear and
monotonic relationships, respectively, between biomarkers
assessed.
The reporting standards of this study fulfil recommendations set
by the STROBE statement for reporting of observational studies
and the REMARK guidelines for tumour prognostic studies.17,18
RESULTS
Determination of collinearity for biomarker combinations
CD3-, CD4-, CD8-, CD20-, FOXP3-, ICOS-, IDO-1- (tumour and
stroma) and PD-L1- (tumour and stroma) expressing cells were
evaluated using singleplex IHC and quantified for use in survival
analysis as described in Fig. 1. Many of these biomarkers are
known to be simultaneously upregulated; therefore, collinearity
was used to indicate a cumulative immune response (Fig. 2a).
Indeed, all biomarkers demonstrated some degree of positive
correlation with each other. Of the biomarkers assessed, the most
significant relationships were observed between CD4 and CD8 IHC
to CD3 IHC (R2= 0.87, P < 0.0001 for CD8 IHC to CD3 IHC and R2=
0.73, P < 0.0001 for CD4 IHC to CD3 IHC). Quantification of IDO-1
IHC in the stroma was also found to demonstrate a moderate
correlation with CD8 IHC (R2= 0.62, P < 0.0001).
The most successful immune-based prognostication algorithms
often combine the assessment of CD3 and CD8 IHC to predict
survival.5 Total CD4- and CD8-expressing cells are analogous for
cumulative CD3 expression; therefore, we anticipate that many
biomarker studies may in fact confer CD4 expression through
quantitation of CD3 and CD8 IHC alone.19 We confirmed, using IHC
in the Epi700 cohort, that the sum of total CD4- and CD8-positive
cells per mm2 has a strong positive relationship with the number
of CD3-positive cells per mm2 (R2= 0.90, P < 0.0001, Fig. 2b).
Surrogate CD4 expression, calculated by the subtraction of CD8
from CD3 IHC, was also found to be representative of CD4 IHC
results; however, the relationship was diminished in comparison
(R2= 0.74, P < 0.0001, Fig. 2c). To understand this better, we
assessed the relationship between CD3-, CD4- and CD8-expressing
cells in a separate cohort of normal colonic epithelium and
colorectal cancer by singleplex IHC and multiplex immunofluor-
escence. Both techniques showed that calculation of a surrogate
CD4 result from CD3 and CD8 cell counts was prone to
misestimation of CD4-expressing cells (Fig. 2d). Multiplex immu-
nofluorescence demonstrated that this difference arose due to
limitations in the detection chemistry for accurately quantifying
weakly positive CD4- and CD8-expressing cells present in the
sample (Fig. 2e).
Determination of an immune-cold phenotype that is predictive of
poor overall survival
To facilitate survival analysis, all biomarkers assessed were
dichotomised using ROC curve analysis within the Epi700
cohort. Univariate and multivariable Cox proportional hazards
for these biomarkers were carried out for each of the individual
biomarkers prior to testing combinations. All the biomarkers
assessed were individually predictive of survival by themselves,
and when adjusted for age, sex, MSI status, stage and treatment,
except PD-L1 stromal IHC (Supplementary Table S2). In addition,
based on the results for their individual survival analysis and
collinearity of the biomarkers assessed, combinations of
dichotomised densities for CD3 and CD8 IHC, CD3, CD4 and
CD8 IHC and CD3, CD4, CD8 and IDO-1 stromal IHC were
assessed for survival outcomes (Supplementary Table S2). Of
these analyses, assessment of low-density cell counts for CD3,
CD4 and CD8 IHC was found to produce the greatest risk of
mortality (HR 1.70, 95% CI: 1.28–2.27).
Due to the variability in TMA design across cohorts, quantifica-
tion of CD3 and CD8 IHC was assessed in a subset of patients (n=
20) in the Epi700 cohort on full-face sections and in TMAs created
from the same block (Supplementary Fig. S2A). Moderate–strong
correlations were found for both CD3 and CD8 IHC quantified in
the invasive margin and central tumour (CD3 invasive margin
R2= 0.65, P < 0.0001; CD3 central tumour R2= 0.94, P < 0.0001;
CD8 invasive margin R2= 0.66, P < 0.0001; CD8 central tumour
R2= 0.97, P < 0.0001; Supplementary Fig. S2B–E). Based on these
data, use of TMA cores did not appear to influence assessment of
CD3 or CD8 IHC, thereby, validating the use of TMAs for the
current study. To consider if assessment of CD3 and CD8 IHC was
warranted in both the invasive margin and central tumour, a
comparison of the percentile rank (i.e., the combined density of
CD3 and CD8 IHC per patient ranked by order of increasing
expression, with and without the inclusion of results from the
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invasive margin) was conducted. A strong correlation in the
percentile rank of these biomarkers in both areas was observed;
therefore, a score based on central tumour expression alone
following the immunohistochemical quantification of CD3- and
CD8-expressing cell density was considered sufficient for use in
the other sample cohorts (Grampian CRC and S:CORT FOCUS) to
classify patients (R2= 0.89, P < 0.0001; Supplementary Fig. S2F). In
order to create an immune classifier that could be replicated for
single-sample analysis, the accuracy and precision of patient
classification using biomarker density for stratification were
compared with patient stratification using percentiles for CD3
and CD8 IHC. Patient stratification defined by density, using
optimised cut-offs (thresholds of 300 and 350 positive cells per
mm2 for CD3 and CD8, respectively), had an accuracy of 88.47%
(95% CI: 85.51–91.01) and precision of 93.99% (95% CI:
91.90–95.56) for predicting the low CD3 and CD8 IHC percentile
group (percentile cut-off of 25%). Low-density CD3 and CD8 IHC
tumours were then further stratified by the addition of CD4 IHC
(threshold of 100 positive cells per mm2).
As nearly all the biomarkers and their combinations were
significant for predicting overall survival, competitive model
selection was utilised. Using AICc on dichotomised immune
biomarker subgroups determined that stratification by combina-
tions of CD3, CD4 and CD8 IHC was the most competitive model
for patient stratification (Delta AICc <4). Combinations of CD3, CD4
and CD8 IHC for predicting outcome were then assessed in the
Grampian Cohort and replicated in the S:CORT FOCUS cohort
using the fixed threshold (Supplementary Table S3). In all three
cohorts, patient stratification combining low-density cell counts
for CD3, CD4 and CD8 IHC was consistently found to be one of the
most competitive models for patient stratification by AICc. In total,
we assessed 1,724 surgically resected primary CRC patients
ranging from stages II to IV, of which, 1449 (84.05%) had complete
results for the whole set of immune biomarkers assessed. Median
survival was 5.80 years, 4.33 years and 1.28 years, for the Epi700
CRC, Grampian CRC and S:CORT FOCUS cohorts, respectively.
Composition of baseline patient characteristics significantly
differed between the three cohorts assessed in the current study;
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however, the age and gender were similar between the Epi700
and Grampian CRC cohorts, and we expected the S:CORT FOCUS
cohort to be significantly different as these patients were enrolled
in a clinical trial (Table 1). The baseline characteristics, survival
outcomes and immune classifications of the S:CORT FOCUS cohort
were well balanced and were representative of the full trial
population associated with first-line 5-Fluorouracil (5FU) or
Oxaliplatin/5-Fluorouracil (FOLFOX) chemotherapy in MRC FOCUS
(Supplementary Table S4). Low-density cell counts for both
immune classifiers (CD3 and CD8 IHC and CD3, CD4 and CD8
IHC) were found to be independent predictors of survival when
adjusted for covariates in the cohorts assessed and in a pooled
analysis stratified by cohort (Fig. 3; Supplementary Table S5).
Stratification by low-density cell counts of CD3, CD4 and CD8 IHC
demonstrated the most significantly reduced 2-year survival in the
S:CORT FOCUS cohort, with only 8.61% of patients alive at 2 years
compared with 23.00% of patients when stratified by low-density
cell counts of CD3 and CD8 IHC alone (Fig. 3g).
Orthogonal characterisation of a CD3, CD4 and CD8 immune-cold
CRC phenotype
In order to assess whether our immune-cold patients were not
already defined by a broader molecular signature, we used
available CRC tumour mutational and transcription profiles in the
S:CORT FOCUS cohort (n= 293). We found that patients who were
immune-cold were more likely to be KRAS mutant (68.97%), have a
CRIS-B transcriptional profile (27.59%) and were not associated
with either MSI status or CMS subtype (P < 0.0179, Table 2).
Differential gene expression analysis was performed using ANOVA
(n= 298). We observed 20 probes to be differentially expressed
between immune-cold and immune–not otherwise (NOS) speci-
fied patients (adjusted P < 0.05). The most common gene
detected in the 20-probe list was SPP1, occurring four times
(ADXEC.2281.C1_x_at, ADXOCEC.14560.C1_at, ADXECAD.5047_at
and ADXEC.2281.C2_x_at) out of a possible seven annotated
probes (Supplementary Tables S6 and S7). Expression of SPP1
mRNA was significantly increased in immune-cold patients
compared with immune NOS (P < 0.0001; Supplementary Fig. S3A).
PCA and hierarchical clustering of patients using these 20
probes demonstrated separation and clustering of transcriptional
profiles for our immune-related groupings (Fig. 4a, b). Many of the
differentially expressed genes are known to be associated
with hypoxia, including SPP1. GSEA for a hypoxia signature
(WINTERS_HYPOXIA_METAGENE) found significant upregulation of
hypoxia-associated genes within immune-cold patients, confirm-
ing this association (adjusted P= 0.0005, Fig. 4c). Dichotomised
expression of the Winters Hypoxia Metagene signature was
significant for predicting overall survival in the S:CORT FOCUS
cohort (HR 1.45 [95% CI: 1.13–1.86], P= 0.0033). The transcrip-
tomic analysis was orthogonally validated by assessment of CAIX
IHC, a robust inducible biomarker for tumour hypoxia, which has
been well characterised and is part of the hypoxia signature
assessed. CAIX IHC was quantified as the number of positive cells
per mm2 (n= 314). A significant increase in CAIX IHC expression
was observed in immune-cold patients compared with immune
NOS, thereby confirming the presence of increased tumour
hypoxia in these patients (P value= 0.0009; Supplementary
Fig. S3B-C). While expression of CAIX IHC was not significant for
predicting overall survival, the overall trend remained the same
(HR 1.27 [95% CI: 0.98–1.65], P= 0.0713; Supplementary Fig. S3D).
Based on hierarchical clustering observed in Fig. 4b, a subgroup of
patients who were both immune NOS and hypoxic were identified
following further stratification of immune-NOS tumours by tissue
hypoxia (Fig. 4e). Interestingly, these patients were less signifi-
cantly hypoxic than immune-cold patients (P= 0.0295). In view of
this observation, we considered these patient groups (immune
Table 1. Baseline characteristics of study patients with immune results, according to cohort.
Epi700 CRC Grampian CRC P value (A) S:CORT FOCUS P value (B) Pooled CRC
(n= 555) (n= 578) (n= 316) (n= 1449)
Median age (interquartile range) 72 (64–78) 71 (62–78) 0.2938 64 (59–70) <0.0001 70 (61–77)
Age – – 0.9010 – <0.0001 –
<70 238 (42.88%) 251 (43.43%) – 234 (74.05%) – 723 (49.90%)
70+ 317 (57.12%) 327 (56.57%) – 82 (25.95%) – 726 (50.10%)
Sex – – 0.3606 – 0.0023 –
Male 306 (55.14%) 302 (52.25%) – 203 (64.24%) – 811 (55.97%)
Female 249 (44.86%) 276 (47.75%) – 113 (35.76%) – 638 (44.03%)
Stage – – 0.0001 – <0.0001 –
II 338 (60.90%) 285 (49.31%) – 0 (0%) – 623 (43.00%)
III 217 (39.10%) 293 (50.69%) – 0 (0%) – 510 (35.20%)
IV 0 (0.00%) 0 (0.00%) – 316 (100%) – 316 (21.81%)
MSI – – <0.0001 – <0.0001 –
Stable 392 (70.63%) 473 (81.83%) – 273 (86.39%) – 1138 (78.54%)
High 118 (21.26%) 97 (16.78%) – 12 (3.80%) – 227 (15.67%)
Missing 45 (8.11%) 8 (1.38%) – 31 (9.81%) – 84 (5.80%)
Adjuvant chemotherapy – – <0.0001 – <0.0001 –
No 401 (72.25%) 0 (0.00%) – 0 (0.00%) – 401 (27.67%)
Yes 154 (27.75%) 0 (0.00%) – 316 (100.00%) – 470 (32.44%)
Missing 0 (0.00%) 578 (100.00%) – 0 (0.00%) – 578 (39.89%)
The data are presented as the number of patients (%). Differences in patient characteristics between the study cohorts for the stage-matched Epi700 and
Grampian CRC in P value (A) and for all the cohorts in P value (B) using ANOVA and Pearson’s chi-squared test for continuous and categorical variables,
respectively.
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cold and immune NOS stratified by either high or low hypoxia) for
survival analysis in the S:CORT FOCUS cohort (Fig. 4f). A 1.5-fold
(HR 1.48 [95% CI: 1.12–1.95], P= 0.0058) and 2.2-fold (HR 2.19
[95% CI: 1.55–3.08], P < 0.0001) increase in risk of death was found
in patients who were immune-NOS hypoxia-high or immune-cold
compared with immune-NOS hypoxia-low patients. In this context,
the combined assessment of CD3, CD4 and CD8 IHC and tumour
hypoxia by the Winters Metagene signature was found to be
an independent predictor for survival when adjusted for clinical
covariates, KRAS status and CRIS-B subtype (Supplementary
Table S8).
DISCUSSION
Spatiotemporal analyses of the immune response have previously
highlighted global depression of the T-cell response in the central
tumour and invasive margin as stage increases, whilst inversely
B-cell expression increases.2 Our study found expression of T-
helper (CD4) to correlate strongly with CD3- and CD8-expressing
cells quantified in the central tumour, when the dichotomised
density of CD4-expressing cells was combined with dichotomised
densities of CD3- and CD8- expressing cells. We found patient
stratification for immune-cold tumours to significantly improve
prognostic power for OS across all stages over assessment by
dichotomised densities of CD3- and CD8-expressing cells alone. Of
the biomarkers assessed, CD3, CD4 and CD8 are principal T-cell
lineage commitment biomarkers essential for the adaptive
immune response.19 Using all three biomarkers provides a more
accurate interpretation of the patient’s native adaptive immune
response than immunohistochemical assessment of CD3- and
CD8-expressing cells alone, and appears to delineate patients who
are truly evading the host immune response. We demonstrate
using singleplex immunohistochemistry and multiplex immuno-
fluorescence that the correlation of CD4 direct quantification
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Fig. 3 Survival estimates in the study cohorts assessed using either CD3 and CD8 immunohistochemistry (IHC) or CD3, CD4 and CD8 IHC.
Kaplan–Meier plots demonstrating univariate survival for immune subgroups defined by assessment of either CD3 and CD8 IHC or CD3, CD4
and CD8 IHC (a–h). Forest plot showing adjusted hazard ratios (95% CI) and corresponding P values for multivariable analysis of immune
subgroups defined by assessment of either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC; multivariable analysis was adjusted for age, sex, MSI
status, stage and treatment in each cohort (i). The pooled analyses for immune subgroups defined by assessment of either CD3 and CD8 IHC
or CD3, CD4 and CD8 IHC are stratified by cohort in the multivariable model. Differences in Kaplan–Meier survival curves are presented as log-
rank P value. Expression cut-offs were optimised in the Epi700 CRC cohort and applied throughout; CD3= 300, CD4= 100, CD8= 350 positive
cells per mm2. Only patients with combined low expression for either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC were considered to have
low expression of these biomarkers.
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versus CD4 as a post calculation from CD3 and CD8 expression
was strong but not perfect, and arises from limitations in the
detection chemistry and its quantification using digital image
analysis. We found that the specific analysis of the density of CD4-
expressing cells in combination with densities of CD3- and CD8-
expressing was found to be the best means to stratify patients
across three independent cohorts. This illustrates the important
but imperfect nature of immunohistochemistry; indeed, the exact
analysis of CD4 obviously provides a significant clinical advantage.
In contrast to previous studies, our study focused on the
central tumour expression of immune and immune-checkpoint
biomarkers only. It was recently demonstrated that assessment
of the immune infiltrate for CD3 and CD8 IHC at either the
invasive margin or central tumour is predictive of survival.20
Indeed, our study confirms that a comparable patient immune
classification can be derived without assessment of the invasive
margin. This has implications for extrapolation of our immune-
cold status as defined by the combined low-density cell counts
for CD3, CD4 and CD8 IHC into scoring of endoscopic diagnostic
biopsy samples that are taken from the luminal aspect and not
the advancing tumour edge.
The robust process exercised in this study to score cancer
immune markers allows a clear-cut determination of the clinical
relevance of not only our immune-cold subgroup, but also its
biological nature. A number of gene expression profiling
approaches, including CMS and CRIS, have been successfully applied
to define particular CRC molecular subtypes.8,9 CRIS classifications
offer a more robust measure of describing CRC molecular subtypes
compared with CMS, as CRIS transcriptional profiles were developed
independent of the tumour stromal content, which can be subject
to sampling bias in CMS classifications.21,22 We demonstrate for the
first time that patients who are immune-cold (when defined by low-
density CD3, CD4 and CD8 IHC expression) are most likely to
associate with the poor prognosis of CRIS-B transcriptional profile,
whilst no association with any particular CMS profile was identified.
Patients with CRIS-B tumours are associated with aggressive disease
and TGF-β signalling. TGF-β signalling has been previously shown to
be enhanced by long-term hypoxia in tissues, and has also been
implicated in immune evasion.23
This study indicates a significant relationship between tumour
hypoxia, the immune response and their combined effect on
patient prognosis in CRC, complementing mechanistic studies
wherein tumour hypoxia has been shown to mediate
immunosuppression.24,25 Differential gene expression analysis of
the immune-cold subgroup showed SPP1 mRNA upregulation in
immune-cold CRC tumours. SPP1 mRNA encodes the Osteopontin
protein that is an established mediator of tumorigenesis, disease
progression and recurrence in cancer, and its expression is known
to be influenced by hypoxia, which has been linked previously
with immune exclusion.26–29 In addition, we determined that our
immune-cold patients are more likely to have KRAS mutations that
have been associated with TGF-β signalling, and therefore
hypoxia, through crosstalk of RAS, and have previously been
demonstrated to have poor prognosis in patients enrolled in the
MRC FOCUS trial.30,31 Clinical trials are currently underway to
assess the clinical applicability of Osteopontin as a blood-based
biomarker for prognosis and monitoring response to treatment.32
Furthermore, it has been proposed that patients with a hypoxia
signature may benefit from more aggressive treatment or
improved oxygen levels in tumours.33 We speculate that joint
assessment of immune-cold status by CD3, CD4 and CD8 IHC in
the resection specimen and Osteopontin expression levels in the
blood would provide a robust approach to identify hypoxic
tumours and monitor in real time their response to therapy.34
To conclude, immunohistochemical assessment of CD3- and
CD8-expressing cells has set the precedent for clinical assessment
of the immune contexture in patients with stage I–III colon cancer.
Critically, we demonstrate that assessment for low-density cell
counts by CD3 and CD8 IHC should be complemented with CD4
IHC expression analysis to enhance patient prognostication and
potential future treatment selection. We also demonstrate that
specific analysis of the invasive front may not be necessary,
opening the test to easier delivery. In contrast to other proposed
methods, we find that addition of CD4 IHC consistently identifies
patients with the worst outcomes in stage II–IV CRC. We establish
for the first time that immune-cold patients by assessment of CD3,
CD4 and CD8 IHC are linked with difficult-to-treat, poor prognosis
hypoxic biology, which may be potentially amenable to targeted
therapy or monitoring for disease progression.
Table 2. MSI status, mutational status and transcriptional subtype of
S:CORT FOCUS study patients, according to immune subgroups
(immune cold vs. immune NOS).
Variable Immune cold Immune NOS P value
(n= 58) (n= 235)
MSI status – – 0.5172
Stable 57 (98.28%) 224 (95.32%) –
High 1 (1.72%) 11 (4.68%) –
APC – – 0.6434
Wild type 12 (20.69%) 40 (17.02%) –
Mutant 46 (79.31%) 195 (82.98%) –
BRAF – – 0.6696
Wild type 49 (84.48%) 206 (87.66%) –
Mutant 9 (15.52%) 29 (12.34%) –
KRAS – – 0.0013
Wild type 18 (31.03%) 131 (55.74%) –
Mutant 40 (68.97%) 104 (44.26%) –
NRAS – – 0.3284
Wild type 57 (98.28%) 221 (94.04%) –
Mutant 1 (1.72%) 14 (5.96%) –
PIK3CA – – 0.1391
Wild type 40 (68.97%) 186 (79.15%) –
Mutant 18 (31.03%) 49 (20.85%) –
TP53 – – 1.0000
Wild type 16 (27.59%) 63 (26.81%) –
Mutant 42 (72.41%) 172 (73.19%) –
CRIS classification – – 0.0179
CRIS-A 12 (20.69%) 40 (17.02%) –
CRIS-B 16 (27.59%) 28 (11.91%) –
CRIS-C 10 (17.24%) 64 (27.23%) –
CRIS-D 4 (6.9%) 24 (10.21%) –
CRIS-E 11 (18.97%) 35 (14.89%) –
Unclassified 5 (8.62%) 44 (18.72%) –
CMS classification – – 0.5616
CMS1 6 (10.34%) 25 (10.64%) –
CMS2 9 (15.52%) 60 (25.53%) –
CMS3 7 (12.07%) 21 (8.94%) –
CMS4 18 (31.03%) 61 (25.96%) –
Unclassified 18 (31.03%) 68 (28.94%) –
The data are presented as number of patients (%). Differences compared
with the immune subgroups using Pearson’s chi-squared test for
categorical variables. Immune cold = patient stratification by collective
low-density cell counts for CD3, CD4 and CD8 IHC; immune–not otherwise
specified (NOS)= any other combination of CD3, CD4 and CD8 IHC
expression.
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